Oxford Biomedica Stock
Oxford Biomedica plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Frank Mathias
- Employees
- 1,017
- Market cap
- £616 M
- IPO
- 13/12/1996
- Web
- www.oxb.com
Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary…
Oxford Biomedica stock: price history
1D
-1.5%
1W
-2.3%
1M
+13.2%
6M
-20.6%
YTD
-17.5%
1Y
-17.5%
2Y
+40.0%
5Y
-66.4%
10Y
+231.6%
Next earnings date
Next earnings date
15/04/2027 (in 180 days)
Volatility around earnings
~29% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Oxford Biomedica stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 29/09/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Oxford Biomedica plc is a biopharmaceutical company specializing in the discovery and manufacturing process of novel cell and gene therapies. The business model is divided into two main segments: a platform technology called LentiVector for gene integration into specific cell types, and the development of proprietary therapeutic products. Through strategic alliances with leading pharmaceutical companies, therapy candidates are being developed for diseases such as Parkinson's and various tumor groups. Additionally, the company leverages research collaborations to improve manufacturing efficiency and technological approaches in viral vectors.
- Revenue model
- Mixed
- Recurring revenue
- Low
- Pricing power
- Weak
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Ask the agents about Oxford Biomedica
Oxford Biomedica stock metrics
P/E
-14.73
P/B
10.6
EV/EBITDA
-50.94
RETURN ON EQUITY
-63.6%
NET MARGIN
-46.3%
DEBT/EQUITY
2.73
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
54.5%
FLOAT SHARES
65,978,144
AVG. DAILY VOLUME (30D)
589,266
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Oxford Biomedica stock
What does Oxford Biomedica do?
Oxford Biomedica plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Frank Mathias, the company employs around 1,017 people.
The IPO was on 13/12/1996; the stock trades on LSE under the ticker OXB.L.
When does Oxford Biomedica report next?
The next earnings date is 15/04/2027.
Around past earnings, price swings were roughly 29% stronger than usual.
Does Oxford Biomedica pay a dividend?
No, Oxford Biomedica currently does not pay a dividend.
Which stocks are comparable to Oxford Biomedica?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Oxford Biomedica stock analyzed?
Clicking "Analyze stock" lets five strategies assess Oxford Biomedica against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.